CSPC Pharmaceutical Group Limited (CSPCY)

OTCMKTS · Delayed Price · Currency is USD
4.140
+0.090 (2.22%)
Jun 4, 2025, 3:13 PM EDT
18.62%
Market Cap 12.90B
Revenue (ttm) 3.73B
Net Income (ttm) 577.85M
Shares Out n/a
EPS (ttm) 0.05
PE Ratio 22.33
Forward PE 17.87
Dividend 0.11 (2.58%)
Ex-Dividend Date Jun 5, 2025
Volume 7
Average Volume 1,935
Open 4.140
Previous Close 4.050
Day's Range 4.140 - 4.140
52-Week Range 2.150 - 4.140
Beta 0.78
RSI 69.08
Earnings Date May 23, 2025

About CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma,... [Read more]

Sector Healthcare
Founded 1992
Employees 21,400
Stock Exchange OTCMKTS
Ticker Symbol CSPCY
Full Company Profile

Financial Performance

In 2024, CSPC Pharmaceutical Group's revenue was 29.01 billion, a decrease of -7.76% compared to the previous year's 31.45 billion. Earnings were 4.33 billion, a decrease of -26.31%.

Financial numbers in CNY Financial Statements

News

Chinese biotech’s mega drug-licensing deals with multinationals surge

A potential multibillion-dollar deal unveiled on Friday by CSPC Pharmaceutical Group is the latest in a growing number of agreements by Chinese biotechnology firms to license development rights for in...

7 days ago - South China Morning Post

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

AstraZeneca (NASDAQ: AZN) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(...

8 months ago - Benzinga

Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Monday. The Dow traded down 0.97% to 41,940.43 while the NASDAQ fell 0.89% to 17,976.85. T...

8 months ago - Benzinga

Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday. The Dow traded down 0.49% to 42,146.78 while the NASDAQ fell 0.36% to 18,073.37. The S...

8 months ago - Benzinga

US Stocks Open Lower; Dow Tumbles Over 150 Points

U.S. stocks traded lower this morning, with the Dow Jones falling more than 150 points on Monday. Following the market opening Monday, the Dow traded down 0.38% to 42,192.55 while the NASDAQ fell 0.29...

8 months ago - Benzinga

AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline

On Monday, AstraZeneca plc (NASDAQ: AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development of an early-stage, novel small-molec...

8 months ago - Benzinga